Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Kilpatrick

Showing results (31-40 of 38) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 38 results.
Proceedings of the National Academy of Sciences of the United States of America|October 28, 1998
EphA4 (Sek1) receptor tyrosine kinase is required for the development of the corticospinal tractM Dottori, L Hartley, M Galea, et al.
BMJ (Clinical Research Ed.)|August 9, 2003
Past exposure to sun, skin phenotype, and risk of multiple sclerosis: case-control studyI A F van der Mei, A-L Ponsonby, T Dwyer, et al.
Journal of Medicinal Chemistry|February 1, 1990
1,9-Alkano-bridged 2,3,4,5-tetrahydro-1H-3-benzazepines with affinity for the alpha 2-adrenoceptor and the 5-HT1A receptorR D Clark, K K Weinhardt, J Berger, et al.
Journal of Neurology|April 12, 2007
Vitamin D levels in people with multiple sclerosis and community controls in Tasmania, AustraliaI A F van der Mei, A-L Ponsonby, T Dwyer, et al.
Journal of Medicinal Chemistry|February 1, 1991
Structure-affinity relationships of 12-sulfonyl derivatives of 5,8,8a,9,10,11,12,12a,13,13a-decahydro-6H-isoquino[2,1-g][1 ,6] naphthyridines at alpha-adrenoceptorsR D Clark, D B Repke, J Berger, et al.
British Journal of Pharmacology|February 1, 1993
The pharmacology of RS-15385-197, a potent and selective alpha 2-adrenoceptor antagonistC M Brown, A C MacKinnon, W S Redfern, et al.
Neurology|July 15, 2011
Current and past Epstein-Barr virus infection in risk of initial CNS demyelinationR M Lucas, A-L Ponsonby, K Dear, et al.
Neurology|April 13, 2005
Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severityR H S R Roxburgh, S R Seaman, T Masterman, et al.
Pageof 4

Showing results (31-40 of 38) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 38 results.
Proceedings of the National Academy of Sciences of the United States of America|October 28, 1998
EphA4 (Sek1) receptor tyrosine kinase is required for the development of the corticospinal tractM Dottori, L Hartley, M Galea, et al.
BMJ (Clinical Research Ed.)|August 9, 2003
Past exposure to sun, skin phenotype, and risk of multiple sclerosis: case-control studyI A F van der Mei, A-L Ponsonby, T Dwyer, et al.
Journal of Medicinal Chemistry|February 1, 1990
1,9-Alkano-bridged 2,3,4,5-tetrahydro-1H-3-benzazepines with affinity for the alpha 2-adrenoceptor and the 5-HT1A receptorR D Clark, K K Weinhardt, J Berger, et al.
Journal of Neurology|April 12, 2007
Vitamin D levels in people with multiple sclerosis and community controls in Tasmania, AustraliaI A F van der Mei, A-L Ponsonby, T Dwyer, et al.
Journal of Medicinal Chemistry|February 1, 1991
Structure-affinity relationships of 12-sulfonyl derivatives of 5,8,8a,9,10,11,12,12a,13,13a-decahydro-6H-isoquino[2,1-g][1 ,6] naphthyridines at alpha-adrenoceptorsR D Clark, D B Repke, J Berger, et al.
British Journal of Pharmacology|February 1, 1993
The pharmacology of RS-15385-197, a potent and selective alpha 2-adrenoceptor antagonistC M Brown, A C MacKinnon, W S Redfern, et al.
Neurology|July 15, 2011
Current and past Epstein-Barr virus infection in risk of initial CNS demyelinationR M Lucas, A-L Ponsonby, K Dear, et al.
Neurology|April 13, 2005
Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severityR H S R Roxburgh, S R Seaman, T Masterman, et al.
Pageof 4